Biopharmaceutical company: AzurRx BioPharma, Inc. (AZRX)

AzurRx BioPharma, Inc. (NASDAQ:AZRX) was founded in 2014 and is headquartered in Brooklyn, New York, USA, with 13 full-time employees. It is a company that researches and develops non-systemic biological agents for the treatment of gastrointestinal diseases.

AzurRx BioPharma

AzurRx BioPharma, Inc. (AZRX):

The AzurRx BioPharma product line includes two therapeutic proteins under development, including:

MS1819, a yeast-derived recombinant lipase, is in phase II clinical trials for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis.

AZX1101, a bacterial-derived enzyme combination, is used to prevent hospital-acquired infections and antibiotic-related diarrhea.

Notify of
Inline Feedbacks
View all Intels

Medical X-ray tube and image processing solution provider: Varex Imaging Corporation (VREX) (2017)

Wireless communication company: Anterix Inc. (ATEX)